Trial Profile
Early Treatment of High Risk Chronic Lymphocytic Leukemia With Alemtuzumab, Rituximab, and PGG Beta-Glucan: A Phase I/II Trial.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Odetiglucan (Primary) ; Alemtuzumab; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 02 Jun 2015 According to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology, due to slow accrual study was terminated.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Status changed from active, no longer recruiting to discontinued, according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.